Why the study?
Clinical practice guidelines on serological screening for CMV during pregnancy are based on limited, low-level evidence and vary in quality, with no universal screening recommendation.
What do clinical practice guidelines recommend regarding serological screening for cytomegalovirus during pregnancy?
Systematic Review (n=13)
What do clinical practice guidelines recommend regarding serological screening for cytomegalovirus during pregnancy?
Current clinical practice guidelines do not recommend routine serological screening for CMV in pregnancy, though the guidelines are generally of low to medium quality and predate emerging interventions.
Guidelines advise against universal CMV serological screening in pregnancy; reinforces selective high-risk testing while highlighting need for updated reviews with emerging interventions.
BACKGROUND: Congenital cytomegalovirus (cCMV) is the most common congenital infection worldwide. cCMV can lead to severe long-term sequelae, including neurological impairment and developmental delay. We performed a systematic review of clinical practice guidelines containing recommendations concerning serological screening for CMV during pregnancy. METHOD: We performed a search of MEDLINE, Turning Research into Practice (TRIP) database and the grey literature for clinical practice guidelines or consensus statements published in the English language from Jan 2010 to June 2022. The quality of the included guidelines was assessed using the Appraisal of Guidelines for Research and Evaluation (AGREE) II instrument. Textual synthesis was used to summarise and compare the recommendations on CMV serological screening in pregnancy. RESULTS: Eleven guidelines and two consensus statements were included. None recommended universal serological screening for CMV in pregnant women; five recommended screening for high-risk women (those with frequent contact with young children). The overall quality of the guidelines varied; most were medium or low. CONCLUSIONS: Although clinical practice guidelines do not actively recommend routine serological screening in pregnancy, most did not meet standard processes for development and predated the emerging data on valaciclovir as a potential intervention. Existing recommendations are underpinned by limited, low-level evidence, exposing the lack of robust data in this area of practice. Further high-level evidence and methodologically robust guidelines are needed to guide clinical practice in this rapidly changing field.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2023) conducted a systematic review in Congenital cytomegalovirus (cCMV) in pregnancy (n=13). Serological screening for cytomegalovirus was evaluated on Recommendations on CMV serological screening in pregnancy. None of the 13 included guidelines recommended universal serological screening for cytomegalovirus in pregnant women, though five recommended screening for high-risk women.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: